Sunil S. Badve

Aug 20, 2024 | medscape.com | Kathy D. Miller |Sunil S. Badve

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Kathy D. Miller, MD: Hi, everyone. I'm Dr Kathy Miller. Welcome to the Medscape InDiscussion podcast series on breast cancer and HER2.

Feb 23, 2024 | nature.com | Sunil S. Badve |Joseph A. Sparano

AbstractWe report the 20-year rate of ipsilateral breast event (IBE) for patients with ductal carcinoma in situ (DCIS) treated with lumpectomy without radiation on a non-randomized prospective clinical trial. Patients were enrolled in cohort 1: low- or intermediate-grade DCIS, size ≤ 2.5 cm (n = 561); or cohort 2: high-grade DCIS, size ≤ 1 cm (n = 104). The Kaplan–Meier method was used to estimate time-to-event distributions.

Apr 6, 2023 | medscape.com | Sunil S. Badve |Yesim Gökmen-Polar

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log outCancel The breast cancer world is somewhat fortunate to have biomarkers that are great at selecting patients most likely to respond to targeted therapies. The stratification of breast cancer into estrogen receptor–positive (ER+) and ER-negative disease has stood the test of time.

Jan 31, 2023 | nature.com | Sunil S. Badve

Artificial intelligence methods are been increasingly used for analysis of pathology slides. In this issue of the Journal, Sandbank et al. describe the validation and utility of a robust second reader system that can distinguish in situ and standfirst invasive carcinomas from non-neoplastic lesions of the breast. The field of pathology is challenging with discordance noted even amongst expert pathologists.